Quick Answer
ZEVRA THERAPEUTICS, INC. reported Total Revenue of $0.00 for fiscal year 2015.
ZEVRA THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | $83.23M +178.9% |
-$105.51M -129.1% |
-$46.05M -72.0% |
-$26.77M -212.9% |
-$8.55M +33.0% |
-$12.76M +48.0% |
| Diluted EPS | $1.35 +159.2% |
-$2.28 | — | — | -$2.11 +34.3% |
-$3.21 |
| Total Assets | $284.73M +59.8% |
$178.13M +3.4% |
$172.33M +49.4% |
$115.34M -13.2% |
$132.94M +1086.0% |
$11.21M +6.7% |
| Cash and Equivalents | $62.41M +84.7% |
$33.78M -21.5% |
$43.05M -34.2% |
$65.47M -41.7% |
$112.35M +2566.7% |
$4.21M +31.0% |
| Long-Term Debt | $61.93M +4.1% |
$59.50M +1074.6% |
$5.07M | — | — | — |
| Stockholders Equity | $154.66M +289.9% |
$39.67M -35.5% |
$61.52M -18.1% |
$75.12M -26.1% |
$101.66M +253.1% |
-$66.41M +10.8% |
| R&D Expense | — | — | — | — | $10.16M +14.9% |
$8.84M -54.5% |
| Operating Income | -$62.94M +27.7% |
-$87.00M -75.4% |
-$49.60M -16.5% |
-$42.56M -650.7% |
$7.73M +237.8% |
-$5.61M +72.4% |
| Shares Outstanding | 56.85M +5.9% |
53.67M +29.2% |
41.53M +20.2% |
34.54M -1.3% |
35.01M +671.5% |
4.54M +99.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2016 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$544.0K | +98.4% | -100.7% |
| Diluted EPS | September 30, 2025 | -$0.01 | +98.6% | -100.8% |
| Total Assets | September 30, 2025 | $270.12M | +41.0% | +5.4% |
| Cash and Equivalents | September 30, 2025 | $54.44M | +0.7% | +14.1% |
| Long-Term Debt | September 30, 2025 | $61.31M | +4.1% | +1.0% |
| Stockholders Equity | September 30, 2025 | $133.16M | +90.9% | +13.6% |
| R&D Expense | March 31, 2022 | $3.08M | +36.1% | +37.7% |
| Operating Income | September 30, 2025 | $4.14M | +115.2% | +105.8% |
| Shares Outstanding | September 30, 2025 | 56.22M | +5.6% | +2.1% |
- ZEVRA THERAPEUTICS, INC. reported Total Revenue of $0.00 for fiscal year 2015.
- ZEVRA THERAPEUTICS, INC. reported Net Income of $83.23 million for fiscal year 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +178.9% in Net Income compared to the prior fiscal year.
- ZEVRA THERAPEUTICS, INC. reported Diluted EPS of $1.35 per share for fiscal year 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +159.2% in Diluted EPS compared to the prior fiscal year.
- ZEVRA THERAPEUTICS, INC. reported Total Assets of $284.73 million for fiscal year 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +59.8% in Total Assets compared to the prior fiscal year.
- ZEVRA THERAPEUTICS, INC. reported Cash and Equivalents of $62.41 million for fiscal year 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +84.7% in Cash and Equivalents compared to the prior fiscal year.
- ZEVRA THERAPEUTICS, INC. reported Long-Term Debt of $61.93 million for fiscal year 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +4.1% in Long-Term Debt compared to the prior fiscal year.
- ZEVRA THERAPEUTICS, INC. reported Stockholders Equity of $154.66 million for fiscal year 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +289.9% in Stockholders Equity compared to the prior fiscal year.
- ZEVRA THERAPEUTICS, INC. reported R&D Expense of $10.16 million for fiscal year 2021.
- ZEVRA THERAPEUTICS, INC. showed an increase of +14.9% in R&D Expense compared to the prior fiscal year.
- ZEVRA THERAPEUTICS, INC. reported Operating Income of -$62.94 million for fiscal year 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +27.7% in Operating Income compared to the prior fiscal year.
- ZEVRA THERAPEUTICS, INC. reported Shares Outstanding of 56.85 million shares for fiscal year 2025.
- ZEVRA THERAPEUTICS, INC. showed an increase of +5.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: